Patent for biologically active product in COVID-19 patients

Patent №4294, 06.07.2022, Bulgarian Patent office „Biologically active product”

Laktera probiotic formula, containing Lactobacillus bulgaricus DWT1 and Streptococcus thermophilus DWT4, modulates the cellular immunity in COVID-19 patients, including pregnant women

ABSTRACT

The COVID-19 pandemic affected the whole world, so the present clinical study contains a very important information. The purpose of the study is to evaluate the effect of a probiotic formula Laktera, containing Lactobacillus bulgaricus DWT1 and Streptococcus thermophilus DWT4, on cellular immunity in COVID-19 patients. The probiotic formula Laktera, at a daily dose of 15-30 g, modulates cellular immunity in COVID-19 patients by increasing lymphocyte populations of NK cells and cytotoxic T lymphocytes and regulating T helpers, thus shortening hospital stay and reducing the economic burden on healthcare systems and employers. There were no intubated patients or deaths in the observed group. Inclusion of a probiotic formula Laktera at a daily dose of 30-45 g in the complex treatment of pregnant patients with COVID-19 after 33rd gestational week leads to a successful control of the viral infection and uncomplicated delivery of healthy COVID-19-free live-born infants. Successful treatment of both pregnant patients with COVID-19 and outpatients indicates that corticosteroid and antibiotic intake can be reduced by adding the probiotic formula Laktera to the complex therapy, and thus reducing the harmful effects of antibiotics and corticosteroids on human microbiome. The use of Lactobacillus bulgaricus DWT1 and Streptococcus thermophilus DWT4 as a probiotic immunotherapy may be the remedy against viral infections in the future.

 

Link to Bulgarian Patent office: https://portal.bpo.bg/bpo_online/-/bpo/utility-model-search